Palopegteriparatide

What is Palopegteriparatide?

Palopegteriparatide is a sustained-release prodrug of parathyroid hormone, developed by Ascendis Pharma and marketed as YORVIPATH. The FDA approved it on 9 August 2024 for the treatment of hypoparathyroidism in adults, following European Commission approval on 20 November 2023. It is the first therapy designed to replace parathyroid hormone continuously rather than to pulse it. That distinction is the entire point of the molecule, and it is where most confusion about it starts. Teriparatide (Forteo) is also PTH 1-34, and it is also injected daily — but it is used for osteoporosis, where the goal is a brief daily spike of PTH that preferentially stimulates osteoblasts over osteoclasts and builds bone. That is an intentionally unphysiological signal, exploiting the fact that pulsatile PTH is anabolic while continuous PTH is catabolic. Hypoparathyroidism is a different problem: patients have too little PTH, chronically, usually because their parathyroid glands were damaged or removed during neck surgery. What they need is the hormone restored across the whole day, which is precisely what pulsatile teriparatide cannot deliver. Palopegteriparatide solves this using the TransCon ('transient conjugation') platform: unmodified PTH(1-34) is attached to an inert methoxy-polyethylene-glycol carrier through a linker that hydrolyses at a predictable rate. The conjugate is inactive; the linker releases free, unmodified PTH slowly and continuously across roughly 24 hours from a single daily injection. The clinical target is not bone density but normal calcium homeostasis without the calcium-and-active-vitamin-D regimen that hypoparathyroid patients otherwise depend on indefinitely — a regimen that itself drives hypercalciuria, nephrocalcinosis, and progressive kidney damage. In the Phase 3 PaTHway trial, 93% of treated patients became independent of conventional therapy at 26 weeks, rising to 95% at 52 weeks, with 24-hour urinary calcium falling from 376 to 195 mg/day.

What Palopegteriparatide Is Investigated For

Palopegteriparatide has one approved indication — hypoparathyroidism in adults — and within it the evidence is genuinely strong for a rare disease. The pivotal trial is PaTHway (NCT04701203), a Phase 3 randomized, double-blind, placebo-controlled study in 84 adults with chronic hypoparathyroidism, randomized 3:1 to palopegteriparatide starting at 18 mcg daily or placebo, both alongside conventional therapy. The composite primary endpoint at 26 weeks — normal albumin-corrected serum calcium, independence from active vitamin D and therapeutic-dose calcium, and no increase in study drug — was met by 79% of treated patients (48/61) versus 5% on placebo (1/21), p<0.0001. Ninety-three percent (57/61) achieved independence from conventional therapy. At 52 weeks, 81% (63/78) still met the composite endpoint, 95% (74/78) were independent of conventional therapy, and none required active vitamin D. The renal story is arguably the most clinically important part and the reason this drug matters beyond symptom control. Conventional hypoparathyroidism management — high-dose calcium plus calcitriol — normalises serum calcium at the cost of dumping calcium into the urine, because the missing PTH is what normally drives renal calcium reabsorption. The result is chronic hypercalciuria, nephrocalcinosis, kidney stones, and declining eGFR over decades. In PaTHway, 24-hour urinary calcium fell from 376 to 195 mg/day, and dedicated analyses reported improved renal function at one year (Rejnmark et al., Adv Ther 2024) sustained through two years (Rejnmark et al., J Bone Miner Res 2026). The Phase 2 PaTH Forward trial showed the same pattern, with urinary calcium falling from 415 to 178 mg/24h and 91% of patients independent of standard of care by week 26; its three-year skeletal-dynamics data (Rubin et al., J Bone Miner Res 2026) extend the bone-turnover picture. The honest caveats: hypercalcemia is common and real — serum calcium exceeded 10.6 mg/dL in 54% of treated patients versus 9.5% on placebo, and exceeded 12 mg/dL in 13% versus none, with symptomatic hypercalcemia in 8% and essentially all of it in the first three months, which is why the label mandates a specific calcium-monitoring schedule during titration. Injection-site reactions affected 39% and vasodilatory symptoms 28%. The label carries a warning about the theoretical osteosarcoma risk inherited from the PTH-analog class, and a rebound effect on abrupt discontinuation has been reported in the literature. Long-term fracture outcomes are not established, and the drug is not approved for acute post-surgical hypoparathyroidism or for pediatric patients.

History & Discovery

Hypoparathyroidism occupied an unusual position in endocrinology for most of the twentieth century: it was one of the few classical hormone-deficiency states not treated by replacing the missing hormone. Diabetes got insulin, hypothyroidism got levothyroxine, growth hormone deficiency got somatropin — but hypoparathyroid patients got high-dose calcium and active vitamin D, a workaround that raises serum calcium through the gut while leaving the renal calcium-handling defect untouched. The consequence, documented across decades of cohort studies, is chronic hypercalciuria, nephrocalcinosis, kidney stones, and progressive renal impairment, alongside a symptom burden that calcium supplementation controls only partially. The obstacle was pharmacokinetic and, in a sense, conceptual. PTH(1-34) had been synthesised and characterised long before, and it reached the market as teriparatide (Forteo, Eli Lilly, approved 2002) — but for osteoporosis, exploiting the discovery that intermittent PTH exposure is anabolic for bone while continuous exposure is catabolic. That same pharmacology made teriparatide a poor hormone-replacement agent: its daily plasma spike clears too quickly to hold calcium stable across 24 hours, and off-label use in hypoparathyroidism was correspondingly disappointing. Full-length recombinant PTH(1-84) reached approval as Natpara (NPS Pharmaceuticals, later Takeda, FDA-approved 2015) and demonstrated that PTH replacement could work, but it was withdrawn from the US market in 2019 over a cartridge issue that risked releasing rubber particulate — leaving patients who had achieved control on it without an option and the field without an approved replacement therapy. Ascendis Pharma approached the problem from its TransCon platform rather than from peptide engineering. TransCon — 'transient conjugation' — attaches an unmodified parent drug to an inert carrier through a linker designed to hydrolyse at a predictable rate, so the conjugate is pharmacologically silent and the parent molecule is released slowly and structurally unaltered. Applied to PTH, this yields continuous rather than pulsatile exposure from a once-daily injection: precisely the profile hormone replacement requires and the one teriparatide cannot provide. Holten-Andersen and colleagues published the design and preclinical development in J Bone Miner Res in 2019, and Karpf and colleagues reported the first-in-human Phase 1 results in the same journal in 2020. Clinical development moved quickly. The Phase 2 PaTH Forward trial (NCT04009291), published by Khan and colleagues in JCEM in 2022, enrolled 59 adults across a four-week blinded phase and a 22-week open-label extension; 91% became independent of standard of care by week 26 and 24-hour urinary calcium fell from 415 to 178 mg/24h. The Phase 3 PaTHway trial (NCT04701203) randomized 84 adults 3:1 to palopegteriparatide or placebo alongside conventional therapy and met its composite primary endpoint at 26 weeks in 79% of treated patients versus 5% on placebo (Khan et al., J Bone Miner Res 2023), with 52-week results confirming durability — 95% independent of conventional therapy, none on active vitamin D (Clarke et al., JCEM 2025). The European Commission approved YORVIPATH on 20 November 2023 following a positive CHMP opinion on 14 September 2023. FDA approval came on 9 August 2024 under NDA 216490 as a Type 1 new molecular entity, for the treatment of hypoparathyroidism in adults. A Japanese Phase 3 trial replicated the findings regionally (Ashida et al., Endocr J 2026), and early US real-world outcomes have been published (Graham et al., Endocr Pract 2025). An August 2026 label revision added hypersensitivity reactions as a formal warning following postmarketing reports of anaphylaxis, angioedema, and urticaria. Commercially the product has been Ascendis's breakout. YORVIPATH generated €252 million in the second quarter of 2026, which the company described on its earnings call as reaching blockbuster status on a run-rate basis in the second year of US launch — a notable outcome for a rare-disease therapy and a reflection of how many hypoparathyroid patients had been left without adequate options after Natpara's withdrawal.

How It Works

The parathyroid glands sit behind the thyroid and release parathyroid hormone, which keeps blood calcium in a narrow range by pulling calcium from bone, telling the kidneys to hold onto calcium instead of losing it in urine, and switching on the active form of vitamin D so the gut absorbs more. In hypoparathyroidism — usually after neck surgery damages or removes these glands — that hormone is missing. The standard fix is large doses of calcium and active vitamin D, which raises blood calcium but does nothing to stop the kidneys leaking calcium into urine, so patients slowly damage their kidneys. Palopegteriparatide replaces the hormone itself. A normal PTH molecule is attached to an inert carrier by a linker that slowly comes apart, so one daily injection releases real PTH steadily across the day instead of in a single spike. That restores kidney calcium handling, which is why most patients in trials were able to stop calcium and active vitamin D entirely.

Parathyroid hormone is an 84-residue peptide whose biological activity resides in its N-terminal fragment; PTH(1-34) retains full agonist activity at the PTH1 receptor (PTH1R), a class B G-protein-coupled receptor expressed on osteoblasts, renal tubular cells, and elsewhere. PTH1R activation couples primarily to Gs, raising intracellular cAMP and activating PKA, with secondary Gq/PLC signalling. The integrated physiological effect maintains serum calcium through three mechanisms: mobilisation of calcium from bone via osteoblast-mediated activation of osteoclastic resorption (osteoclasts lack PTH1R and are recruited indirectly through RANKL); increased calcium reabsorption in the distal renal tubule with reciprocal phosphate excretion; and upregulation of renal 1-alpha-hydroxylase, converting 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D and thereby increasing intestinal calcium absorption. The pharmacological consequence that defines this drug class is that PTH exposure pattern determines direction of effect. Intermittent, short-duration PTH exposure preferentially stimulates osteoblast proliferation, differentiation, and survival while inhibiting sclerostin, producing a net anabolic 'window' — the basis for teriparatide and abaloparatide in osteoporosis. Continuous PTH exposure instead sustains RANKL-driven osteoclastic resorption and is net catabolic for bone, but it is also what normal parathyroid physiology looks like and what calcium homeostasis requires. Hypoparathyroidism is a deficiency state, so the therapeutic objective is continuous replacement, not pulsatile stimulation — which is why daily teriparatide, whose plasma exposure is a brief spike, performs poorly off-label in this indication. Palopegteriparatide is built to deliver continuous exposure from a once-daily injection. Unmodified PTH(1-34) is conjugated to an inert methoxy-polyethylene-glycol carrier through a TransCon transient linker. In the conjugated state the molecule is pharmacologically inactive and shielded from proteolysis and renal clearance; the linker then undergoes predictable, pH- and temperature-dependent hydrolysis, releasing free unmodified PTH(1-34) at a controlled rate that sustains physiological-range PTH concentrations across approximately 24 hours. The design intent — validated in the preclinical work of Holten-Andersen and colleagues (J Bone Miner Res 2019) and the first-in-human Phase 1 study by Karpf and colleagues (J Bone Miner Res 2020) — is a flat exposure profile rather than the Cmax-and-trough curve of an injected native peptide. Clinically, restoring continuous PTH signalling corrects the specific defect that conventional therapy cannot address. High-dose oral calcium plus calcitriol raises serum calcium by brute force through the gut, but without PTH the distal tubule fails to reabsorb the filtered load, producing chronic hypercalciuria and its sequelae — nephrocalcinosis, nephrolithiasis, and progressive decline in glomerular filtration. Palopegteriparatide restores renal calcium reabsorption directly, which is the mechanism behind the reduction in 24-hour urinary calcium from 376 to 195 mg/day observed in PaTHway and the improvements in renal function reported at one and two years.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Palopegteriparatide:

• 01Long-term skeletal outcomes and fracture risk — continuous PTH exposure is theoretically net catabolic for bone, and while the Phase 2 three-year skeletal-dynamics data (Rubin et al., 2026) begin to address this, fracture outcomes over decades of replacement are not established.
• 02Whether the renal-function improvements observed at one and two years translate into preserved glomerular filtration, fewer kidney stones, and less nephrocalcinosis across decades — the outcome that would most decisively justify hormone replacement over conventional therapy, and one that requires registry-scale follow-up.
• 03Osteosarcoma risk under continuous rather than pulsatile PTH exposure — the reassuring human data come from teriparatide's twenty-year pharmacovigilance record, which covers a different exposure pattern. The label's warning reflects class inheritance rather than palopegteriparatide-specific evidence.
• 04Optimal management of discontinuation — rebound hypocalcemia has been documented in a case report, but there is no established taper protocol or evidence base for stopping the drug safely.
• 05Pediatric hypoparathyroidism — not studied, and the osteosarcoma warning's flag on open epiphyses is a real barrier to studying it. Children with congenital or post-surgical hypoparathyroidism currently have no PTH-replacement option.
• 06Acute and early post-surgical hypoparathyroidism — explicitly outside the studied population, yet this is where a large share of incident cases arise, and the question of whether early replacement improves recovery or merely masks it is unaddressed.
• 07Pregnancy and lactation — calcium homeostasis changes substantially in pregnancy and no safety or dosing data exist.
• 08Head-to-head comparison against full-length PTH(1-84) approaches and against emerging PTH-pathway agents — no comparative trials exist, and the withdrawal of Natpara from the US market in 2019 removed the natural comparator before such a trial could be run.

Forms & Administration

YORVIPATH is supplied as three multi-dose prefilled pens, colour-coded by dose range: 168 mcg/0.56 mL with a blue button covering 6, 9, and 12 mcg doses; 294 mcg/0.98 mL with an orange button covering 15, 18, and 21 mcg; and 420 mcg/1.4 mL with a burgundy button covering 24, 27, and 30 mcg. Administration is once daily by subcutaneous injection, and the label is explicit that the full daily dose must be delivered in a single injection — using two injections to reach a dose increases variability in the amount of drug actually delivered and is the subject of a specific labeled warning about unintended calcium changes. The starting dose is 18 mcg daily, titrated in 3 mcg increments or decrements to a maintenance dose between 6 and 30 mcg, with 30 mcg the labeled maximum. Before initiation, and within the preceding two weeks, serum 25-hydroxyvitamin D should be confirmed normal and albumin-corrected serum calcium confirmed at or above 7.8 mg/dL. Serum calcium is checked 7 to 10 days after the first dose and after every dose change, then every 4 to 6 weeks at maintenance. Titration is asymmetric by design: increases no more often than every 7 days, decreases as often as every 3 days. Initiation and titration belong with an endocrinologist experienced in calcium disorders.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

YORVIPATH is approved only for hypoparathyroidism in adults and has not been studied in acute post-surgical hypoparathyroidism or in pediatric patients. The figures above reproduce the FDA label for reference and are not prescribing guidance. Hypoparathyroidism management requires specialty endocrinology care, and the calcium-monitoring schedule during titration exists because hypercalcemia in this setting can be serious.

Timeline of Effects

Common Questions

Who Palopegteriparatide Is NOT For

Drug & Supplement Interactions

Palopegteriparatide's interactions are dominated by its effect on serum calcium rather than by pharmacokinetic competition. The peptide payload is cleared by peptidase degradation and receptor-mediated uptake with the PEG carrier cleared renally, and there is no meaningful hepatic cytochrome P450 involvement, so classical CYP-based interactions are not expected. Digoxin is the interaction the label singles out. Hypercalcemia increases myocardial sensitivity to digitalis glycosides, so a patient stabilised on digoxin whose serum calcium rises on palopegteriparatide can develop digoxin toxicity at an unchanged digoxin dose. Patients on digoxin need closer calcium and digoxin monitoring, particularly during titration when calcium is least stable. Calcium and active vitamin D are the co-administered agents that matter most in practice, and the interaction is intended rather than incidental. Conventional therapy is tapered as palopegteriparatide takes over, and failing to taper is a route to hypercalcemia — which is much of why the label mandates calcium checks 7 to 10 days after initiation and after each dose change. Thiazide diuretics reduce urinary calcium excretion and can compound the risk of hypercalcemia in this setting; loop diuretics do the reverse. Drugs that lower serum calcium or affect bone turnover — bisphosphonates, denosumab, calcimimetics such as cinacalcet, and systemic corticosteroids — can shift the calcium target and complicate titration. Because the drug produces vasodilatory effects, with flushing reported in 28% of treated patients and a labeled warning for orthostatic hypotension, initiation is worth flagging in patients on antihypertensives, nitrates, or other vasodilators. Patients should disclose all prescription medications, over-the-counter calcium and vitamin D products, and supplements to the managing endocrinologist, since over-the-counter calcium is both extremely common and directly relevant here.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions